JP7325959B2 - 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体 - Google Patents

腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体 Download PDF

Info

Publication number
JP7325959B2
JP7325959B2 JP2018552062A JP2018552062A JP7325959B2 JP 7325959 B2 JP7325959 B2 JP 7325959B2 JP 2018552062 A JP2018552062 A JP 2018552062A JP 2018552062 A JP2018552062 A JP 2018552062A JP 7325959 B2 JP7325959 B2 JP 7325959B2
Authority
JP
Japan
Prior art keywords
antibody
cells
tumor
cancer
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513725A (ja
JP2019513725A5 (https=
Inventor
セルジオ ケサダ
カール ペグス
アルセ フレデリック バーガス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2019513725A publication Critical patent/JP2019513725A/ja
Publication of JP2019513725A5 publication Critical patent/JP2019513725A5/ja
Application granted granted Critical
Publication of JP7325959B2 publication Critical patent/JP7325959B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018552062A 2016-04-07 2017-03-17 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体 Active JP7325959B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201605947 2016-04-07
GB1605947.9 2016-04-07
PCT/EP2017/056469 WO2017174331A1 (en) 2016-04-07 2017-03-17 Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion

Publications (3)

Publication Number Publication Date
JP2019513725A JP2019513725A (ja) 2019-05-30
JP2019513725A5 JP2019513725A5 (https=) 2020-04-23
JP7325959B2 true JP7325959B2 (ja) 2023-08-15

Family

ID=58358618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018552062A Active JP7325959B2 (ja) 2016-04-07 2017-03-17 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体

Country Status (15)

Country Link
US (2) US20190135925A1 (https=)
EP (1) EP3440109B1 (https=)
JP (1) JP7325959B2 (https=)
KR (2) KR20190017735A (https=)
CN (1) CN109476739A (https=)
AU (1) AU2017247880B2 (https=)
BR (1) BR112018070636A2 (https=)
CA (1) CA3020204A1 (https=)
CL (2) CL2018002828A1 (https=)
ES (1) ES3046543T3 (https=)
IL (1) IL262129B2 (https=)
MX (1) MX2018012319A (https=)
PL (1) PL3440109T3 (https=)
RU (1) RU2759970C2 (https=)
WO (1) WO2017174331A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
KR20190017735A (ko) 2016-04-07 2019-02-20 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
EP3737698A2 (en) * 2018-01-10 2020-11-18 BioInvent International AB Novel combination and use of antibodies
AU2019221544B2 (en) * 2018-02-13 2025-07-10 Precision Biologics, Inc. Methods and compositions for targeting Treg cells
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
EP3566718A1 (en) * 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
WO2020028269A2 (en) * 2018-07-30 2020-02-06 Invenra Inc. Multispecific treg binding molecules
WO2020177627A1 (zh) * 2019-03-02 2020-09-10 上海一宸医药科技有限公司 一种双特异抗体
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
ES2975410T3 (es) * 2020-02-13 2024-07-05 UCB Biopharma SRL Anticuerpos biespecíficos que se unen a HVEM y CD9
JP2023525060A (ja) * 2020-05-14 2023-06-14 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途
KR20230107641A (ko) 2020-11-13 2023-07-17 아이바이오, 인크. Cd25 항체
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
US20240352136A1 (en) 2021-09-02 2024-10-24 Hoffmann-La Roche Inc. Antibodies for the treatment of aml
TW202336033A (zh) * 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
EP4514388A1 (en) 2022-04-26 2025-03-05 F. Hoffmann-La Roche AG Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024151091A1 (ko) * 2023-01-11 2024-07-18 한국과학기술원 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물
WO2024165454A1 (en) 2023-02-06 2024-08-15 F. Hoffmann-La Roche Ag Combination therapy and uses thereof
TW202444760A (zh) 2023-03-29 2024-11-16 日商第一三共股份有限公司 抗ｃｄ２５抗體及抗ｃｄ２５抗體－藥物複合體

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535883A (ja) 2005-04-15 2008-09-04 ノバルティス アクチエンゲゼルシャフト 免疫治療におけるｃｄ２５抗体の使用
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US20090304711A1 (en) * 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
KR20190017735A (ko) 2016-04-07 2019-02-20 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
GB201712032D0 (en) * 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
EP4514388A1 (en) * 2022-04-26 2025-03-05 F. Hoffmann-La Roche AG Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535883A (ja) 2005-04-15 2008-09-04 ノバルティス アクチエンゲゼルシャフト 免疫治療におけるｃｄ２５抗体の使用
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US20140294759A1 (en) 2013-03-15 2014-10-02 Seung Chu Targeting regulatory t cells with heterodimeric proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cancer Vaccines, 2009, Vol.1174, pp.99-106
Eur. J. Immunol., 2010, Vol.40, pp.3325-3335
JOHN H SAMPSON; ET AL，A PILOT STUDY OF IL-2Rα BLOCKADE DURING LYMPHOPENIA DEPLETES REGULATORY T-CELLS AND CORRELATES WITH ENHANCED IMMUNITY IN PATIENTS WITH GLIOBLASTOMA，PLOS ONE，2012年02月27日，VOL:7, NR:2，PAGE(S):E31046/1-11，https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0031046&type=printable
Science Translational Medicine, 2012, Vol.4, No.134, Article No.134ra62, pp.1-9
Trends in Immunology, 2015, Vol.36, No.6, pp.325-336

Also Published As

Publication number Publication date
IL262129B1 (en) 2025-03-01
EP3440109A1 (en) 2019-02-13
IL262129A (en) 2018-11-29
EP3440109C0 (en) 2025-07-23
EP3440109B1 (en) 2025-07-23
RU2018135247A3 (https=) 2021-01-20
BR112018070636A2 (pt) 2019-02-05
US20230265200A1 (en) 2023-08-24
ES3046543T3 (en) 2025-12-02
AU2017247880A1 (en) 2018-11-15
MX2018012319A (es) 2019-06-06
CL2019003498A1 (es) 2020-05-29
IL262129B2 (en) 2025-07-01
CN109476739A (zh) 2019-03-15
AU2017247880B2 (en) 2024-07-11
RU2759970C2 (ru) 2021-11-19
CA3020204A1 (en) 2017-10-12
JP2019513725A (ja) 2019-05-30
RU2018135247A (ru) 2020-05-12
US20190135925A1 (en) 2019-05-09
CL2018002828A1 (es) 2019-03-08
KR20220032642A (ko) 2022-03-15
PL3440109T3 (pl) 2025-12-01
KR20190017735A (ko) 2019-02-20
WO2017174331A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
US20230265200A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
JP7225135B2 (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
WO2022003156A1 (en) Ccr8 non-blocking binders
JP7458973B2 (ja) 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
KR20200140315A (ko) 항-cd27 항체 및 그의 용도
WO2016011069A1 (en) Medical uses of cd38 agonists (antibodies)
US20240052050A1 (en) Multispecific antibodies for the treatment of cancer
RU2839380C1 (ru) Fc-оптимизированные антитела к cd25 для истощения опухолеспецифических клеток
HK1262659A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
NZ786026A (en) Anti CD25 Fc gamma receptor bispecific antibodies for tumor specific cell depletion
HK40018012A (en) Compounds and methods for tumour-specific cell depletion
HK40016585B (zh) 用於肿瘤特异性细胞消耗的fc优化的抗cd25
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190129

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20191115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230524

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230802

R150 Certificate of patent or registration of utility model

Ref document number: 7325959

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150